PAREXEL International Corporation, a global provider of biopharmaceutical services, announced an alliance with South Korean CHA Medical Group (CHA) to enhance early phase clinical development in Korea.
The collaboration is designed to provide biopharmaceutical companies with comprehensive services that leverage PAREXEL’s global clinical research and regulatory expertise with CHA’s experience conducting early phase studies in Korea.
A growing hub for drug development, Korea is ranked sixth in the world for the number of clinical trials conducted in the country, and is an attractive location for early phase trials due to government investment in the industry and access to patients. Additionally, Korea’s regulatory requirements, modeled after the U.S. Food and Drug Administration (FDA), enable sponsors to use the data from early clinical studies conducted in the country for global development.
PAREXEL has 28 offices and 7,150 employees across the Asia Pacific region, and established operations in Korea in 2000. Through the partnership, PAREXEL and CHA have recently completed a Phase I First-in-Human clinical trial at CHA’s flagship facility in Seoul, South Korea.